In summary, our study demonstrates the crucial role of the miR-339-5p/Nnat pathway in synaptic and calcium dysfunction in early AD, indicating that Nnat could be a potential therapeutic biomarker for early stage AD. Here, NNAT is linked to Alzheimer disease.